Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 2;12(10):2709-2711.
doi: 10.1080/21645515.2016.1219003.

Vaccine adjuvants: Why and how

Dennis Christensen  1
Affiliations

Vaccine adjuvants: Why and how

Dennis Christensen. Hum Vaccin Immunother. .

Abstract

Novel vaccine strategies include the so-called subunit vaccines, which encompass only the part of the pathogen to which immune recognition results in protection. The high purity of these vaccines make adverse events less likely, but it also makes the vaccines less immunogenic and therefore potentially less effective. Vaccine adjuvants that increase and modulate the immunogenicity of the vaccine are therefore added to solve this problem. Besides aluminum salts, which have been used in vaccines for 90 years, a number of novel vaccine adjuvants have been included in licensed vaccines over the last 30 years. Increasing insight into immunological mechanisms and how to manipulate them has replaced empirical with rational design of adjuvants, leading to vaccine adjuvants with increased and customized immunogenicity profiles without compromising vaccine safety.

Keywords: adjuvant; immunogenicity; immunostimulators; sub-unit; vaccine.

PubMed Disclaimer

References

    1. WHO Polio cases worldwide. www.polioeradication.org. Last accessed June2016
    1. WHO and UNICEF (July 2015) Guidance on how to prioritize globally constrained BCG vaccine supply to countries. http://www.who.int/immunization/diseases/tuberculosis/BCG-country-priori.... Last accessed June2016
    1. Glenny A, Pope C, Waddington H, Falacce U. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926; 29:31-40; http://dx.doi.org/10.1002/path.1700290106 - DOI
    1. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 2013; 12(1):13-30; PMID:23256736; http://dx.doi.org/10.1586/erv.12.140 - DOI - PubMed
    1. Glück R, Metcalfe IC. New technology platforms in the development of vaccines for the future. Vaccine 2002; 20(Suppl 5):B10-6; PMID:12477412; http://dx.doi.org/10.1016/S0264-410X(02)00513-3 - DOI - PubMed

MeSH terms